Share Pam R. Taub, MD, FACC - Making the Case for Novel LDL-C–Lowering Therapies in the Management of Pediatric and Adult Homozygous Familial Hypercholesterolemia

Copy link

October 09, 2023

Pam R. Taub, MD, FACC - Making the Case for Novel LDL-C–Lowering Therapies in the Management of Pediatric and Adult Homozygous Familial Hypercholesterolemia

16 minutes

Please visit answersincme.com/TJX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses low-density lipoprotein (LDL) receptor–independent therapies for homozygous familial hypercholesterolemia (HoFH) via two patient case studies. Upon completion of this activity, participants should be better able to: Identify patients with HoFH through differential diagnosis; Review the clinical profiles of novel strategies to reduce LDL cholesterol in patients with HoFH that work independently of LDL receptors; and Outline patient-centered strategies to maximize quality of life for patients with HoFH on lipid-lowering therapies.

...more